Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $3.28 in the prior trading day, scPharmaceuticals Inc (NASDAQ: SCPH) closed at $3.24, down -1.22%. In other words, the price has decreased by -$1.22 from its previous closing price. On the day, 0.52 million shares were traded. SCPH stock price reached its highest trading level at $3.32 during the session, while it also had its lowest trading level at $3.15.
Ratios:
Our goal is to gain a better understanding of SCPH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.89 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 1.71 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 07, 2023, initiated with a Buy rating and assigned the stock a target price of $20.
On December 01, 2022, Cowen started tracking the stock assigning a Outperform rating and target price of $25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’24 when ORBIMED ADVISORS LLC bought 500,000 shares for $4.00 per share. The transaction valued at 2,000,000 led to the insider holds 5,806,670 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SCPH now has a Market Capitalization of 164131600. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.35 while its Price-to-Book (P/B) ratio in mrq is 5.28.
Stock Price History:
The Beta on a monthly basis for SCPH is 0.11, which has changed by -0.37760913 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, SCPH has reached a high of $6.54, while it has fallen to a 52-week low of $3.08. The 50-Day Moving Average of the stock is -8.04%, while the 200-Day Moving Average is calculated to be -24.49%.
Shares Statistics:
The stock has traded on average 431.53K shares per day over the past 3-months and 282510 shares per day over the last 10 days, according to various share statistics. A total of 50.04M shares are outstanding, with a floating share count of 34.54M. Insiders hold about 30.97% of the company’s shares, while institutions hold 61.42% stake in the company. Shares short for SCPH as of 1735603200 were 6461747 with a Short Ratio of 14.97, compared to 1732838400 on 5713041. Therefore, it implies a Short% of Shares Outstanding of 6461747 and a Short% of Float of 14.6.
Earnings Estimates
The market rating for scPharmaceuticals Inc (SCPH) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.31 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.48 and -$2.02 for the fiscal current year, implying an average EPS of -$1.78. EPS for the following year is -$1.08, with 3.0 analysts recommending between -$0.95 and -$1.3.
Revenue Estimates
4 analysts predict $12.07M in revenue for the current quarter. It ranges from a high estimate of $12.2M to a low estimate of $12M. As of the current estimate, scPharmaceuticals Inc’s year-ago sales were $6.1MFor the next quarter, 4 analysts are estimating revenue of $14.43M. There is a high estimate of $15.5M for the next quarter, whereas the lowest estimate is $12.8M.
A total of 3 analysts have provided revenue estimates for SCPH’s current fiscal year. The highest revenue estimate was $36.3M, while the lowest revenue estimate was $36.22M, resulting in an average revenue estimate of $36.25M. In the same quarter a year ago, actual revenue was $13.59MBased on 6 analysts’ estimates, the company’s revenue will be $84.09M in the next fiscal year. The high estimate is $96.4M and the low estimate is $74M.
